Skip to main content

Advertisement

Log in

A fluid biomarker accurately detects tau aggregate pathology in Alzheimer’s disease

  • Research Briefing
  • Published:

From Nature Medicine

View current issue Submit your manuscript

Cost-effective fluid biomarkers for tau aggregate pathology would improve the diagnostic and prognostic work-up of Alzheimer’s disease and facilitate the discovery of anti-tau therapies. We identified MTBR-tau243 as a specific marker for tau aggregate pathology that could be implemented in clinical practice and trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1: Associations between CSF biomarkers and amyloid and tau pathology.

References

  1. Hansson, O. Biomarkers for neurodegenerative diseases. Nat. Med. 27, 954–963 (2021). A review of AD and other neurodegenerative diseases, with a focus on biomarkers currently available.

    Article  CAS  PubMed  Google Scholar 

  2. Ossenkoppele, R. et al. Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline. Nat. Med. 28, 2381–2387 (2022). A paper showing that tau pathology is a much stronger predictor of cognitive decline than Aβ, even during the earliest stages of the disease.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Ossenkoppele, R., van der Kant, R. & Hansson, O. Tau biomarkers in Alzheimer’s disease: towards implementation in clinical practice and trials. Lancet Neurol. 21, 726–734 (2022). A review of the currently available markers of tau pathology, and recent anti-tau trials in AD.

    Article  CAS  PubMed  Google Scholar 

  4. Salvadó, G. et al. Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads. EMBO Mol. Med. 15, e2463 (2023). A neuropathology-based study showing that there are not any fluid biomarkers specific for tau aggregate pathology available at present.

    Article  Google Scholar 

  5. Horie, K., Barthelemy, N. R., Sato, C. & Bateman, R. J. CSF tau microtubule binding region identifies tau tangle and clinical stages of Alzheimer’s disease. Brain 144, 515–527 (2021). A small pilot study showing that MTBR-tau243 can be detected in CSF and can be associated with tau tangles.

    Article  PubMed  Google Scholar 

Download references

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This is a summary of: Horie, K. et al. CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer’s disease. Nat. Med. https://doi.org/10.1038/s41591-023-02443-z (2023).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

A fluid biomarker accurately detects tau aggregate pathology in Alzheimer’s disease. Nat Med 29, 1912–1913 (2023). https://doi.org/10.1038/s41591-023-02468-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-023-02468-4

  • Springer Nature America, Inc.

Navigation